Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (131-140 of 207) with videos related to

Pageof 21
Sort By:
Lancet (London, England)|July 10, 2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialJosé Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn, et al.
Plos One|November 19, 2014
Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconvertersRomina Soledad Coloccini, Dario Dilernia, Yanina Ghiglione, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 16, 2019
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT TrialMargaret Johnson, Princy Kumar, Jean-Michel Molina, et al.
Journal of Virology|October 23, 2015
Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular CytotoxicityMaría Julia Ruiz, Yanina Ghiglione, Juliana Falivene, et al.
AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.
The Lancet. HIV|December 23, 2023
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Jean-Michel Molina, Pedro Cahn, et al.
AIDS Research and Therapy|February 14, 2023
Identifying the needs of older people living with HIV (≥ 50 years old) from multiple centres over the world: a descriptive analysisTomás Martín Grosso, Diana Hernández-Sánchez, Gordana Dragovic, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trialDarrell H S Tan, Janet M Raboud, Leah Szadkowski, et al.
Lancet Regional Health. Americas|October 10, 2022
A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV careOmar Sued, Diego Cecchini, María José Rolón, et al.
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.
Pageof 21

Showing results (131-140 of 207) with videos related to

Sort By:
Pageof 21
Lancet (London, England)|July 10, 2007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialJosé Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn, et al.
Plos One|November 19, 2014
Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconvertersRomina Soledad Coloccini, Dario Dilernia, Yanina Ghiglione, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 16, 2019
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT TrialMargaret Johnson, Princy Kumar, Jean-Michel Molina, et al.
Journal of Virology|October 23, 2015
Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular CytotoxicityMaría Julia Ruiz, Yanina Ghiglione, Juliana Falivene, et al.
AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.
The Lancet. HIV|December 23, 2023
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Jean-Michel Molina, Pedro Cahn, et al.
AIDS Research and Therapy|February 14, 2023
Identifying the needs of older people living with HIV (≥ 50 years old) from multiple centres over the world: a descriptive analysisTomás Martín Grosso, Diana Hernández-Sánchez, Gordana Dragovic, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trialDarrell H S Tan, Janet M Raboud, Leah Szadkowski, et al.
Lancet Regional Health. Americas|October 10, 2022
A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV careOmar Sued, Diego Cecchini, María José Rolón, et al.
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.
Pageof 21